Positioning Biosimilars in Clinical Practice

Panelists discuss how biosimilars are gaining traction through targeted education, cost-effectiveness analysis, and rigorous clinical validation, with providers increasingly integrating these alternatives by addressing knowledge barriers and demonstrating comparable therapeutic performance.

EP: 1.Clinical Value of Biosimilars and the Role of Interchangeability

EP: 2.The Economic Impact of Biosimilars

EP: 3.Best Practices for Employers to Maximize Uptake of Biosimilars

EP: 4.The Role of Private Label Agreements in Enhancing Access to Biosimilars

EP: 5.Key Structural and Operational Considerations for Biosimilar Adoption

Now Viewing

EP: 6.Positioning Biosimilars in Clinical Practice

EP: 7.Assessing Patient Confidence With Biosimilars

EP: 8.The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars

EP: 9.The Growing Market for Biosimilars

EP: 10.Biosimilar Pricing Strategies: Understanding High-WAC and Low-WAC Models

EP: 11.The Biosimilar Shift: How PBMs Are Reshaping Formularies

EP: 12.The Road to Biosimilar Adoption: Navigating Interchangeability

EP: 13.How the IRA is Reshaping Biosimilar Adoption

EP: 14.Cost Savings Potential Associated With the Use of Biosimilars

EP: 15.Examining the Role of Interchangeability in Clinical Practice

EP: 16.Optimizing the Implementation of Biosimilars Into Formularies

EP: 17.Key Pearls for Collaborating With Manufacturers for Successful Uptake of Biosimilars

EP: 18.Working With Policy Makers to Effectively Implement Biosimilars

Video content above is prompted by the following:

• How are providers positioning biosimilars in their treatment algorithms? What can be done to increase provider confidence in biosimilars?

Related Videos

Related Content

Advertisement

July 25th 2025

Navigating Pediatric Hidradenitis Suppurativa: A Q&A on Early Diagnosis and Effective Treatment

Laura Joszt, MA Robyn Guo Ku Tarannum Jaleel, MD, MS Daniela Kroshinsky, MD, MPH

Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 24th 2025

Federal Recommendations for Vaccines Containing Thimerosal Rescinded

Julia Bonavitacola

Thimerosal, a mercury-based preservative, has been incorrectly linked to the development of autism by antivaccine groups.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 23rd 2025

Single-Dose Fosfomycin Found as Safe, Effective as Other Antibiotics for Uncomplicated UTIs

Brooke McCormick

Fosfomycin proved to be a safe, effective alternative for treating uncomplicated urinary tract infections (UTIs), potentially reducing antibiotic resistance and costs.

July 23rd 2025

Real-World Study Finds Brentuximab Vedotin With Chemo Is Safe, Effective in First-line Treatment of PTCL

Mary Caffrey

Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line treatment in newly diagnosed peripheral T-cell lymphoma (PTCL).

Related Content

Advertisement

July 25th 2025

Navigating Pediatric Hidradenitis Suppurativa: A Q&A on Early Diagnosis and Effective Treatment

Laura Joszt, MA Robyn Guo Ku Tarannum Jaleel, MD, MS Daniela Kroshinsky, MD, MPH

Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 24th 2025

Federal Recommendations for Vaccines Containing Thimerosal Rescinded

Julia Bonavitacola

Thimerosal, a mercury-based preservative, has been incorrectly linked to the development of autism by antivaccine groups.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 23rd 2025

Single-Dose Fosfomycin Found as Safe, Effective as Other Antibiotics for Uncomplicated UTIs

Brooke McCormick

Fosfomycin proved to be a safe, effective alternative for treating uncomplicated urinary tract infections (UTIs), potentially reducing antibiotic resistance and costs.

July 23rd 2025

Real-World Study Finds Brentuximab Vedotin With Chemo Is Safe, Effective in First-line Treatment of PTCL

Mary Caffrey

Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line treatment in newly diagnosed peripheral T-cell lymphoma (PTCL).